Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2014

May 7, 2014

32254_dirs_2014-05-07_b80110fe-b912-4056-914b-ff88de9aec76.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2014-05-05

Reporting Person: Ashton Paul (Director, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-05-05 Common Stock M 3500 $1.13 Acquired 444241 Direct
2014-05-05 Common Stock S 3500 $4.01 Disposed 440741 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-05-05 Stock Option (Right to Buy) $1.13 M 3500 Disposed 2018-11-18 Common Stock (3500) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 16781 Indirect

Footnotes

F1: Shares sold pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person with respect to the Common Stock of the Issuer.

F2: The option was granted on 11/18/2008 and vested in four equal annual installments beginning on the first anniversary of the date of grant.

F3: Shares held by the Paul Ashton Children's Irrevocable Trust, of which the Reporting Person's minor children are the beneficiaries. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.